SCHEMBL21854047

SCHEMBL21854047

Cn1cc(C(=O)NC(Cc2ccccc2)C(=O)C(N)=O)c(-c2cnc3ccccc3c2)n1

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CAPN1 P07384 18/20 0.56
▸ DCAF1 Q9Y4B6 1/20 0.48
▸ CTSL P07711 1/20 0.46
▸ CTSB P07858 1/20 0.46
▸ NTSR1 P30989 1/20 0.45
▸ CTSS P25774 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21854267 0.90 CAPN1 (0.54) CAPN1CTSLCTSBNTSR1CTSS
SCHEMBL20028410 0.90 CAPN1 (0.59) CAPN1CTSS
SCHEMBL20028411 0.87 CAPN1 (0.55) CAPN1DCAF1CTSLCTSB
SCHEMBL23268990 0.87 CAPN1 (0.59) CAPN1DCAF1CTSS
SCHEMBL20028632 0.87 CAPN1 (0.59) CAPN1DCAF1CTSS
SCHEMBL22886441 0.85 CAPN1 (0.55) CAPN1CTSS
SCHEMBL29962127 0.85 CAPN1 (0.55) CAPN1CTSS
SCHEMBL22886099 0.84 CAPN1 (0.59) CAPN1CTSS
SCHEMBL21854026 0.84 CAPN1 (0.53) CAPN1CTSLCTSBCTSS
SCHEMBL20027495 0.83 DCAF1 (0.53) CAPN1DCAF1CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324814-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS INC (US) 2022-10-13 — — US disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed
US-20200123114-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123114-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF CAPNS1, CAPN9, CAPN1 CAPN1 3/4885DCAF1 3091/4885CTSL 234/4885
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885DCAF1 3091/4885CTSL 234/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 CAPN1 4/4885DCAF1 3598/4885CTSL 242/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 CAPN1 3/4885DCAF1 3091/4885CTSL 234/4885
US-20220324814-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF CAPNS1, CAPN9, CAPN1 CAPN1 3/4885DCAF1 3091/4885CTSL 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback